REG - ValiRx PLC - Directorate Changes

ValiRxAnnouncement

22/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV4146La&default-theme=true

RNS Number : 4146L  ValiRx PLC  22 April 2024

ValiRx plc

 

("ValiRx" or the "Company")

 

Directorate Changes

 

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to announce
that, further to the announcements of 29 February and 19 March 2024, the
Company has appointed Martin Gouldstone and Adrian de Courcey as Non-executive
Directors with immediate effect, following completion of standard regulatory
due diligence. In addition, Ray Horn has been appointed as a Board observer.

 

Director Appointments

 

Adrian de Courcey

 

Adrian de Courcey is a business executive with experience in both corporate
and entrepreneurial environments in the UK and internationally. He began his
career with KPMG and held strategy roles with Shell and Johnson & Johnson,
with experience within the SME sector and built a transportation business.
Adrian graduated from the University of Warwick and obtained an MBA from the
University of Cambridge in 2020.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Adrian Michael Patrick de
Courcey (aged 46):

 

 Current Directorships               Previous Directorships held in the past five years
 Inishbofin Holdings Limited         Leofric Biomass Limited
 Mike De Courcey Travel Limited(1)   West Midlands Transport Information Services Limited(2)
 Tydfil Training Consortium Limited

(1) Adrian de Courcey was appointed as a director of Mike De Courcey Travel
Limited on 1 July 2006. On 3 August 2021 the company was placed in a creditors
voluntary liquidation. The liquidation process is ongoing.

 

(2) Adrian de Courcey was appointed as a director of West Midlands Transport
Information Services Limited on 5 October 2011. On 21 September 2018 the
company appointed a voluntary liquidator to conduct a members voluntary
liquidation. The Company was dissolved 30 November 2021 with no creditor
shortfall.

 

Adrian de Courcey holds 871,036 ordinary shares and 22,955 warrants over new
ordinary shares in the Company.

 

There is no further information regarding Adrian de Courcey required to be
disclosed under the AIM Rules.

 

Martin Gouldstone

 

Martin is currently CEO of Oncimmune Holdings plc and has 30 years of
corporate finance and business development experience in contract research
organisations, healthcare and pharmaceutical sectors. Previously, Martin was a
Global Senior Vice President of Business Development at Owkin, Inc., where he
managed the commercial teams in the USA and Europe and led new strategic
research partnerships. More recently, Martin was Chief Business Officer at
Sensyne Health; Global Senior Vice President and Head of Capital Solutions for
Syneos Health; Chief Business Officer at BenevolentAI.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Martin John Gouldstone (aged
57):

 

 Current Directorships                   Previous Directorships held in the past five years
 hVIVO PLC (previously Open Orphan PLC)  Orthopaedic Research UK
 Novara Therapeutics Limited             ( )
 Oncimmune Holdings PLC
 Sempiternum Ltd

 

Martin Gouldstone does not hold any ordinary shares or warrants over new
ordinary shares in the Company.

 

There is no further information regarding Martin Gouldstone required to be
disclosed under the AIM Rules.

 

Additional Updates

 

Further to the announcement of 4( )March 2024, in the interest of ensuring a
proportionate number of non-executive directors following today's appointments
and taking into account the Company's size, Luke Cairns has advised, and the
Company has agreed, that he will not be joining the board as a non-executive
director at this time.

 

Ray Horn has been appointed as a Board observer with immediate effect.

 

 

Kevin Cox, Chairman commented: "I am pleased that Adrian and Martin have
joined the Board of ValiRx as the first step towards establishing a new
management team. I look forward to their participation and providing
commercial expertise to help guide the Company. I would also like to thank
Luke for his time and efforts in working with us during this time of
transition."

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

 

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 2476 796496

                                                   www.valirx.com

 Dr Suzanne Dilly, CEO                             Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz/)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEASLFALSLEFA